Consistent with this, we found that several BRAF-mutated melanoma cell lines are more sensitive to CDK12 inhibition (THZ531) (IC50 values between 55 nM and 220 nM) than melanocytes (IC50 > 1 μM) (Fig. 3b). The gene discussed is BRAF; the disease is melanoma.